Physician profile
Stephen J Daly
NPI 1063437523
$1,226.87
in general payments reported to CMS, 2019-2025
15 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.22 · 2020: $50.43 · 2021: $18.01 · 2022: $150 · 2023: $180 · 2024: $506 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $363.13 | 2022-2025 | (5044) Mcot, Extended Holter, Mcot |
| Novartis Pharmaceuticals Corporation | $186.62 | 2020-2025 | |
| Atricure, INC. | $167.10 | 2023-2024 | |
| Amgen INC. | $153.25 | 2019-2024 | Repatha |
| Pfizer INC. | $108.42 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $48.66 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.42 | 2019-2020 | |
| Baxter Healthcare | $33.45 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Impulse Dynamics (USA) INC. | $31.87 | 2025 | Optimizer |
| Alnylam Pharmaceuticals INC. | $21.65 | 2024 | Amvuttra |
| Medicomp INC | $20.22 | 2025 | Telepatch Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $14.97 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $14.81 | 2025 | Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $14.33 | 2024 | Eliquis |
| Boston Scientific Corporation | $13.97 | 2024 | Bodyguardian |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.